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A B S T R A C T
Background: In infants with phenylketonuria (PKU), dietary management is based on lowering and titrating
phenylalanine (Phe) intake from breast milk or standard infant formula in combination with a Phe-free infant
formula in order to maintain blood Phe levels within target range. Professionals use diﬀerent methods to feed
infants with PKU and our survey aimed to document practices across Europe.
Methods: We sent a cross sectional, survey monkey® questionnaire to European health professionals working in
IMD. It contained 31 open and multiple-choice questions. The results were analysed according to diﬀerent
geographical regions.
Results: Ninety-ﬁve centres from 21 countries responded. Over 60% of centres commenced diet in infants by age
10 days, with 58% of centres implementing newborn screening by day 3 post birth. At diagnosis, infant hospital
admission occurred in 61% of metabolic centres, mainly in Eastern, Western and Southern Europe. Breastfeeding
fell sharply following diagnosis with only 30% of women still breast feeding at 6months.
53% of centres gave pre-measured Phe-free infant formula before each breast feed and 23% alternated breast
feeds with Phe-free infant formula. With standard infant formula feeds, measured amounts were followed by
Phe-free infant formula to satiety in 37% of centres (n=35/95), whereas 44% (n=42/95) advised mixing both
formulas together. Weaning commenced between 17 and 26 weeks in 85% centres, ≥26 weeks in 12% and <
17weeks in 3%.
Discussion: This is the largest European survey completed on PKU infant feeding practices. It is evident that
practices varied widely across Europe, and the practicalities of infant feeding in PKU received little focus in the
PKU European Guidelines (2017). There are few reports comparing diﬀerent feeding techniques with blood Phe
control, Phe ﬂuctuations and growth. Controlled prospective studies are necessary to assess how diﬀerent infant
feeding practices may inﬂuence longer term feeding development.
1. Background
Infants with phenylketonuria (PKU) with blood Phe> 360 μmol/L
are treated with a low phenylalanine (Phe) diet following diagnosis
after a positive newborn screening test. This involves restricting natural
protein intake by lowering the amount of breast milk or standard infant
formula given in combination with a protein substitute (Phe-free infant
formula). The practical feeding process can be conducted in diﬀerent
ways and it is likely that practices may vary throughout Europe.
Although it is well established that commencing treatment early is as-
sociated with better outcome in PKU, it is possible that the choice and
application of infant feeding practices may also aﬀect longer-term
feeding development and nutritional outcome. In the general popula-
tion, breastfeeding is associated with less overweight and obesity and a
higher IQ [1]. Also a higher protein intake in infancy may be associated
with a later risk of obesity [2]. Approaches to the delivery of early care,
support and education in PKU may aﬀect parental acceptance of the
condition and their attitude towards dietary management. On diagnosis
of PKU, parents are expected to manage the dietary treatment im-
mediately, and so are forced into a situation of coping (what must be
done here and now) rather than being given time to adjust to the di-
agnosis of PKU in their infant [3]. Feeding infants with PKU is un-
doubtedly challenging. The goal of nutritional management is to
maintain blood Phe levels between 120 and 360 μmol/L as re-
commended by the PKU European guidelines [4]. Timing of treatment
commencement is determined by the age of newborn screening. If the
age of newborn screening is later, in infants with classical PKU it is
probable that blood Phe concentrations will be higher, and in turn it
will take longer to stabilise blood Phe control, although this remains
unreported in screened infants. Later newborn screening will require
rapid reduction of blood Phe, possibly leading to temporary cessation of
breastfeeding and overall, this may cause additional parental anxiety
associated with feeding. Also, in slightly later diagnosed infants, well-
established feeding routines pre-diagnosis may be more challenging to
change, and the introduction of a strong tasting Phe-free infant amino
acid formula (providing non Phe amino acids with other essential nu-
trients) may be diﬃcult. The European guidelines recommend that
treatment should commence by 10 days of age, however it is unknown
how many European centres are able to achieve this target [4].
Dietary management in infancy is based on lowering and titrating
dietary Phe intake from breast milk or standard infant formula so that
blood Phe concentrations are maintained within target range whilst
achieving optimal growth and development. There appears no universal
approach to feeding infants with PKU, with health professionals
adopting many diﬀerent practices. For example, when partial breast
milk is given, techniques may include: 1) a measured amount of ex-
pressed breast milk prior to a Phe-free infant formula [5], 2) a pre-
measured amount of Phe-free infant formula prior to breastfeeding until
satiety [6–8], 3) a pre-measured amount of Phe-free infant formula
prior to ‘time-controlled’ breastfeeding, and 4) alternate breast and Phe-
free infant formula feeds [9–11]. When a measured amount of standard
infant formula is given, this may be administered pre or post Phe-free
infant formula or both feeds may be mixed together [10, 12]. In addi-
tion, whilst it is known that breastfeeding management strategies vary
among countries and between treatment centres within countries [7,
13–16], it is unknown if the type of strategy will impact on the duration
of breastfeeding in PKU.
In our survey, we aimed to study dietary treatment methods in in-
fants with PKU across European centres.
2. Material and methods
A cross sectional, survey monkey® questionnaire was sent to
European IMD health professionals (dietitians, nutritionists and med-
ical doctors) who were either members of the ‘The Society for the Study
of Inborn Errors of Metabolism’ (SSIEM) or who have participated in
previous European surveys assessing dietary practices [17–19]. The
questionnaire was composed of 31 open and multiple-choice questions
asking questions about the infant age at newborn screening and dietary
feeding practices at diagnosis and during the ﬁrst 12months of life. The
questionnaire was written in English but linguistic support (Portuguese,
French, Spanish and Italian) was provided by the ﬁrst author [AP] to
clarify any queries. Only one answer per centre was accepted from
health professionals and participants were instructed to answer each
question according to their general clinical practice rather than with
individual patient cases.
The questionnaire responses were analysed by individual centre in
addition to the geographical region of each centre. The results were
analysed in two parts 1) processes related to early feeding and 2)
weaning processes (introduction of low protein foods, normal foods and
change in protein substitutes).
In part 1, the following information was collected: number of infants
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diagnosed with PKU each year, infant age at newborn-screening, age of
starting diet, hospital or home care at diagnosis, frequency of blood Phe
monitoring, breastfeeding prevalence at diagnosis and post diagnosis,
and duration of breastfeeding. Breastfeeding was deﬁned as the only
source of feed intake before diagnosis. Post diagnosis of PKU breast-
feeding was deﬁned as breast milk given with Phe-free infant formula.
Detail about the diﬀerent methods of administering Phe-free infant
formula with breast milk or standard infant formula was collected. Data
on total protein requirements was also collected. Part 2 results will be
published separately.
3. Results
3.1. Participants
Ninety-ﬁve centres from 21 European countries responded to the
survey monkey® questionnaire. Centres were grouped into the fol-
lowing geographical regions to analyse the results:
• Southern Europe (n=30 centres): Portugal (n=7 centres), Italy
(n=6 centres), Spain (n=9 centres), Greece (n=2 centres) and
Turkey (6 centres);
• Western Europe A (n=16 centres): Belgium (n=6 centres), France
(n=5 centres) and The Netherlands (n= 5 centres);
• Western Europe B (n=15 centres): Germany (n=13 centres) and
Austria (n=2 centres);
• Northern Europe (n=24 centres): UK (n=17 centres), Sweden
(n=3 centres), Norway (n= 1 centre), Denmark (n=1 centre),
Finland (n=1 centre) and Ireland (n=1 centre);
• Eastern Europe (n=10 centres): Latvia (n=1 centre), Poland
(n=6 centres), Slovakia (n=1 centre), Hungary (n=1 centre)
and Estonia (n= 1 centre).
The number of new infants diagnosed with PKU annually in each
centre varied widely but over half of the respondents only had 1 to 3
new cases per year. The number of new infants diagnosed per year in
centres were: 1–3 cases per annum, 52% (n=49/95); 4–10 cases, 31%
(n=29/95); 11–20 cases, 11% (n= 10/95); 21–30 cases, 1% (n=1/
95); and≥ 30 cases, 2% (n=2/95).
New born screening occurred by day 3 of infant age in over 50% of
centres: day 1, 2%, (n=2/95) centres; day 2, 24%, (n=23/95); day 3,
32% (n=30/95); day 4–6 days, 38% (n=36/95); day 7–10, 3%
(n= 3/95); and > day 10, 1% (n=1/95) centres.
3.2. Dietary practices after diagnosis
At diagnosis, infants were admitted to hospital in 61% of metabolic
centres (n=58/95 centres). The centres more likely to admit patients
to hospital at the time of diagnosis were in Eastern Europe, Western
Europe and Southern Europe (Fig. 1). Over 60% of centres (Southern
Europe: 53%; Western Europe A: 69%; Western Europe B: 93%;
Northern Europe: 63%; Eastern Europe: 30%) had commenced a low
Phe diet by 10 days of age (< 3 days, 1% [n=1/95]; 4–10 days, 61%
[n=58/95]; 11–14 days, 31% [n=29/95]; 15–20 day, 6% [n=6/
95];> 21 days, 1% [n=1/95] of centres). Only 42% of centres were
likely to have 76% or more of their infants on breast feeds at the time of
diagnosis, with breastfeeding being highest in Southern and Western
Europe (Fig. 2, Table 1). The numbers of infants who continued
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Fig. 2. Percentage of centres breastfeeding infants with PKU at time of diagnosis and post diagnosis.
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breastfeeding fell markedly and only 26% of centres maintained 76% or
more of their infants on breast feeds beyond the diagnostic time (Fig. 2,
Table 2). Overall, breastfeeding duration was short with a mean of:
4 weeks in 9% (n=9/95), 5–17weeks in 26% (n=25/95),
18–26 weeks in 34% (n=32/95), 27–52 weeks in 24% (n=23/95)
and > 1y, 6% (n= 6/95) of centres. Diﬀerent geographical results are
presented in Table 3. Only 17% of centres (n=16/95) pre-measured
expressed breast milk.
In breastfeeding infants, 53% (n=50/95 centres) of centres gave a
measured amount of Phe-free infant formula before each breast feed to
satiety (without any time limited breast feeds); 11% (n=10/95) gave a
pre-measured amount of Phe-free infant formula before time limited
breast feeds and 6% (n=6/95) gave breast feeds followed by a mea-
sured amount of Phe-free infant formula from a bottle. Twenty-three
per cent (n=22/95 centres) gave alternate breast feeds with phe-free
infant formula and 7% (n=7/95 centres) used diﬀerent practices.
When a standard infant formula feed was given for the Phe source,
8% (n=8/95 centres) of centres gave a measured amount of Phe-free
infant formula ﬁrst followed by measured amount of standard infant
formula, whereas 37% (n=35/95) gave a measured amount of stan-
dard infant formula followed by Phe-free infant formula to satiety.
Forty-four per cent of centres (n=42/95) advised mixing Phe-free
formula together with standard infant formula, 8% (n=8/95 centres)
alternated feeds of standard infant formula with Phe-free infant formula
and 2% (n= 2/95 centres) used diﬀerent practices. Fig. 3 indicates the
diﬀerent practices by geographical regions.
The total protein requirements (including both natural protein and
protein equivalent from protein substitute) prescribed by centres in the
ﬁrst 12months of life were: 1.5 g/kg/day, 1% (n= 1/95); 2 g/kg/day,
24% (n=23/95); 2.5 g/kg/day, 36% (n=34/95); 3 g/kg/day, 36%
(n= 34/95 centres); 3.5 g/kg/day, 1% (n=1/95 centres) and un-
deﬁned 2% (n=2/95 centres). Table 4 presents the amounts
Table 1
Infants that were breast fed at the time of PKU diagnosis in the diﬀerent European geographical regions.
Geographical region % of centres with speciﬁc % of infants with PKU that were breast-fed AT TIME OF DIAGNOSIS
< 10% 11–30% 31–50% 51–75% 76–100%
Southern Europe 10% (3/30) 7% (2/30) 7% (2/30) 16% (5/30) 60% (18/30)
N=30
Western Europe A 0 13% (2/16) 19% (3/16) 44% (7/16) 25% (4/16)
N=16
Western Europe B 0 0 0 47% (7/15) 53% (8/15)
N=15
Northern Europe 12% (3/24) 12% (3/24) 38% (9/24) 12% (3/24) 26% (6/24)
N=24
Eastern Europe 0 10% (1/10) 10% (1/10) 40% (4/10) 40% (4/10)
N=10
Table 2
Infants that were breast fed post PKU diagnosis in the diﬀerent European geographical regions.
Geographical region % of centres with speciﬁc % of infants with PKU that CONTINUE to breastfeed AFTER diagnosis
< 10% 11–30% 31–50% 51–75% 76–100%
Southern Europe 23% (7/30) 10% (3/30) 10% (3/30) 20% (6/30) 37% (11/30)
N=30
Western Europe A 13% (2/16) 19% (3/16) 25% (4/16) 13% (2/16) 31% (5/16)
N=16
Western Europe B 0 0 13% (2/15) 67% (10/
15)
20% (3/15)
N=15
Northern Europe 17% (4/24) 17% (4/24) 29% (7/24) 17% (4/24) 20% (5/24)
N=24
Eastern Europe 10% (1/10) 20% (2/10) 20% (2/10) 40% (4/10) 10% (1/10)
N=10
Table 3
Duration of infant breastfeeding by European geographical region (%).
Geographical region Duration of breastfeeding
4 weeks 5–17weeks 18–26weeks 27–52weeks >1y
Southern Europe 23% (7/30) 27% (8/30) 23% (7/30) 10% (3/30) 17% (5/30)
N=30
Western Europe A 6% (1/16) 50% (8/16) 25% (4/16) 19% (3/16) 0
N=16
Western Europe B 0 13% (2/15) 47% (7/15) 40% (6/15) 0
N=15
Northern Europe 4% (1/24) 21% (5/24) 42% (10/24) 33% (8/24) 0
N=24
Eastern Europe 0 20% (2/10) 40% (4/10) 30% (3/10) 10% (1/10)
N=10
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prescribed by diﬀerent geographical regions.
The majority of centres (85% [n=81/95]) started weaning with
phe-free solids between 17 and 26weeks, 3% of centres (n= 3/95)
before 17 weeks and 12% (n=11/95) after 26 weeks of age.
During the ﬁrst year of life following blood Phe stabilization, blood
Phe levels were monitored by centres: twice weekly by 16% (n=15/
95); weekly by 69% (n=66/95); once every 2 weeks by 11% (n=10/
95) and monthly by 4% (n=4/95) of centres.
4. Discussion
This is the largest survey conducted on infant feeding practices in
PKU throughout Europe. Methods used to feed infants with PKU varied
widely across centres. Our study indicated that over 60% of centres had
started dietary treatment by the time infants were 10 days of age. It is
encouraging that many centres met the European PKU guidelines [4].
Earlier newborn screening prevents severe neurological impairment as
well as permitting timely implementation of the Phe restricted diet,
although it is unclear how this impacts on long term feeding.
The need to admit infants into hospital at the time of diagnosis is
associated with availability of local resources, traditional local practices
or early testing for BH4 responsiveness. It is unknown if hospital ad-
mission is associated with earlier stabilization of blood Phe levels, al-
leviation or heightening of parental anxiety.
Although the use of breastfeeding in PKU is well established, the
percentage of centres breastfeeding was highly variable between re-
gions: Southern, Western (Germany and Austria) and Eastern Europe
had the highest incidence of breastfeeding at the time of diagnosis, but
the numbers fell in both Eastern and Western European countries fol-
lowing diagnosis. Some countries in Northern Europe (mainly UK) had
a lower rate of breastfeeding at diagnosis but infants were a little older
at diagnosis with a mean diagnostic age of> 10 day.
In PKU, breastfeeding maintenance is more complex than in the
general population. The availability of home support with reliable and
consistent advice is important, but at diagnosis mothers have to make
immediate decisions about feeding choice. Blood Phe levels above
1000 μmol/L at diagnosis may require cessation of breastfeeding for 24
to 48 h, and any diﬃculty in re-establishing breast feeds, may lead to
breastfeeding failure. Mothers are commonly overwhelmed and dis-
tressed; they are uncertain and anxious about the amount of breast milk
consumed and the potential harm this may cause to the baby.
With breastfeeding, the most common practice was to administer a
pre-measured amount of Phe-free formula prior to breast-feeds.
Surprisingly, alternating feeds of breast milk and Phe-free infant for-
mula was practiced in 23% of centres. There are few reports describing
the use of this method [6, 10, 11]. It will probably work well in early
infancy when Phe requirements are high, but as this decreases with age,
it may be necessary to further limit the number of daily breast feeds
oﬀered and replace this with additional Phe-free formula. This may lead
to uneven distribution of Phe intake causing increased ﬂuctuation in
blood Phe concentrations. Prospective, controlled studies examining
this technique are required to study 24 h blood Phe variation but the
simplicity of this technique is very attractive.
Some centres ask mothers to only express breast milk so that it can
be pre-measured, but there are now many longitudinal retrospective
studies on large numbers of infants that show that giving pre-measured
Phe-free infant formula before breastfeeding to satiety is safe and sa-
tisfactory blood Phe control and growth is achievable [8, 20, 21].
Only 30% of breastfeeding women continued to breast feed beyond
6months. This was highly variable from 19% centres in Western Europe
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Fig. 3. Description by diﬀerent European geographical re-
gions of how Phe–free infant formula is given when a stan-
dard formula is used to provide the phenylalanine source.
Abbreviations: A: give a measured amount of Phe-free infant
formula ﬁrst followed by a measured amount of standard
infant formula; B: give a measured amount of standard infant
formula followed by Phe-free infant formula to satiety; C: mix
Phe-free infant formula with standard infant formula; D: al-
ternate feeds of standard infant formula and Phe-free Infant
formula.
Table 4
Total protein prescribed (g/kg/day) to infants with PKU by diﬀerent European geographical regions (%).
Geographical
region
Total protein prescription
1.5 g/kg/day 2.0
g/kg/day
2.5 g/kg/day 3.0 g/kg/day 3.5 g/kg/day other
Southern Europe 3% (1/30) 13% (4/30) 43% (13/30) 37% (11/30) 4% (1/30) 0
N=30
Western Europe A 0 38% (6/16) 56% (9/16) 6% (1/16) 0 0
N=16
Western Europe B 0 73% (11/15) 20% (3/15) 0 0 7% (1/15)
N=15
Northern Europe 0 4% (1/24) 21% (5/24) 75% (17/24) 0 4% (1/24)
N=24
Eastern Europe 0 10% (1/10) 40% (4/10) 50% (5/10) 0 0
N=10
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A to 40% in Western Europe B and Eastern Europe. Overall this data
conﬁrms previous ﬁndings, which clearly and consistently indicate that
breastfeeding is commonly for a short duration in PKU [8, 10, 11, 14,
15, 22–25]. Interestingly, even though Northern Europe is the region
with a lower percentage of breastfeeding infants at diagnosis, their
percentage of continuation is similar to other regions (33%) and by
6months of age, breastfeeding rates (34%) were close to the normal
population [26].
For infants who were given standard infant formula the most pop-
ular method was mixing standard infant formula together with Phe-free
infant formula, although this technique is under researched [11, 12]. It
is certainly more convenient for parents but when Phe sources are in-
troduced from food, a lower volume of standard infant formula is mixed
with the Phe-free infant protein substitute leading to a stronger taste of
the latter and possibly lower acceptance by the infant. There are few
longitudinal studies examining diﬀerent methods of bottle feeding in
PKU and the impact on blood Phe control as well as later adherence to
protein substitute.
The amount of total protein prescribed (97% prescribed ≥2 g/kg/
day) was higher than the European guidelines (2017) [4]. In the Eur-
opean guidelines, it is recommended an additional 40% more protein
from Phe-free amino acids is given compared with the WHO/FAO/UNU
2007 safe levels of protein intake [27], but this ﬁgure is empirically
based. There have been reports of poor growth in young children with
PKU [4], and Hoeksma demonstrated that a higher intake of natural
protein intake, rather than the total protein intake was an important
factor in head circumference growth [28]. There are also reports to
indicate that higher doses of protein substitute improve natural protein
tolerance in young children [4]. We consider further evidence is re-
quired before centres reduce doses of protein substitute in infancy ac-
cording to the new European guidelines (2017) [4].
This study has several limitations. It was cross-sectional rather than
prospective. Data about blood Phe control measurements were not
collected. Data was collected about general practice rather than in-
dividual prescriptions. Only one questionnaire was completed by each
PKU centre and it was possible that diﬀerent professionals may have
had diﬀerent practices within the same centre. Moreover, diﬀerent
access to special formula, experience of professionals and ability to do
home blood sampling may have inﬂuenced practices.
5. Conclusion
Even though PKU is the most commonly studied inherited metabolic
disorder, infant feeding practices varied widely across Europe.
Interestingly, little attention was paid to this subject in the PKU
European Guidelines (2017) [4] and there are few reports comparing
diﬀerent feeding techniques with blood Phe control, stability of blood
Phe levels and growth. Controlled prospective studies are needed to
assess how diﬀerent practices inﬂuence these outcomes in order to
deﬁne the optimal infant feeding practices in PKU.
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